miR-30a-5p preserves cardiac homeostasis by reprogramming metabolic checkpoints in hypertrophic cardiomyopathy

Xiao-Cheng Zhang1, Chan Wu1, Yun-Da Li1

  • 1Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361009, China.

Life Sciences
|December 18, 2025
PubMed

Insights

MicroRNA-30a-5p protects against pathological cardiac hypertrophy by maintaining mitochondrial function and redox balance. This study reveals its therapeutic potential in treating heart conditions.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • MicroRNA Therapeutics

Background:

  • MicroRNA-30a-5p (miR-30a-5p) is implicated in myocardial infarction but its role in cardiac hypertrophy is unclear.
  • Pathological cardiac hypertrophy is a major risk factor for heart failure.

Purpose of the Study:

  • To investigate the therapeutic potential and molecular mechanisms of miR-30a-5p in cardiac hypertrophy.
  • To elucidate the role of miR-30a-5p in cardiac function, remodeling, and mitochondrial homeostasis.

Main Methods:

  • Transgenic knockout mice and angiotensin II (Ang II)-induced models of cardiac hypertrophy.
  • Transverse aortic constriction (TAC) to induce pressure overload.
  • Cellular assays, RNA-sequencing, and mitochondrial function analysis.

Main Results:

  • miR-30a-5p was upregulated in cardiac hypertrophy models.
  • miR-30a-5p deficiency worsened hypertrophy and cardiac remodeling.
  • miR-30a-5p overexpression protected against hypertrophy-induced dysfunction and fibrosis.
  • miR-30a-5p preserved mitochondrial bioenergetics and reduced oxidative stress.

Conclusions:

  • miR-30a-5p acts as a protective factor against pathological cardiac hypertrophy.
  • Therapeutic strategies targeting miR-30a-5p may preserve mitochondrial integrity and redox homeostasis in hypertrophic hearts.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
426
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436